AC Immune First Half 2026 Financial and Corporate Update
Focused portfolio of wholly-owned programs approach near-term clinical catalysts as partnered programs generate milestone payments
- Key advances across pipeline, with further near-term clinical results anticipated for H2 2026
- Phase 2 VacSYn trial of ACI-7104 in Parkinson’s disease supported by a $4 million grant from The Vijay and Marie Goradia Charitable Foundation
- Morphomer small molecule program targeting intracellular Tau progresses with Lilly
-
Initiation of Alzheimer’s disease AD4 cohort in ABATE trial triggered $12 million milestone payment from Takeda
-
Cash resources of CHF 75.4 million as of June 30, 2026, provide funding into Q4 2027
Lausanne, Switzerland, August 5, 2026 — AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company developing targeted therapeutics for neurodegenerative diseases, today provided a corporate and financial update for the half-year ended June 30, 2026.
